Meta-Analysis of Methamphetamine Modulation on Amyloid Precursor Protein through HMGB1 in Alzheimer's Disease

Area of Science:

• Neuroscience
• Molecular Biology
• Pharmacology

Background:

• Amyloid-beta (Aβ) deposition, resulting from amyloid-beta precursor protein (APP) cleavage, is a key Alzheimer's disease (AD) biomarker.
• Methamphetamine (METH) use is increasingly recognized for its potential neurotoxic effects, warranting investigation into its molecular impact on AD pathology.

Purpose of the Study:

• To elucidate the molecular mechanisms through which methamphetamine (METH) influences Alzheimer's disease (AD) by modulating amyloid-beta precursor protein (APP) expression.
• To identify specific molecular pathways and signaling molecules involved in METH-induced changes in APP expression.

Main Methods:

• Utilized QIAGEN Ingenuity Pathway Analysis (IPA) for meta-analysis of molecular mechanisms.
• Collected data on molecules affected by METH and APP from the QIAGEN Knowledge Base (QKB).
• Employed the "Molecule Activity Predictor" to simulate METH exposure and identify affected molecules and their relationship with APP expression.

Main Results:

• Identified 78 overlapping molecules between METH and APP datasets.
• Eight molecules were found to be affected by METH and activate APP expression (p=0.000453).
• The High Mobility Group Box protein 1 (HMGB1) signaling pathway was significantly associated with METH-affected molecules and showed increased APP expression via HMGB1 (p<0.00001).

Conclusions:

• The High Mobility Group Box protein 1 (HMGB1) signaling pathway plays a crucial role in METH-induced modulation of APP expression.
• HMGB1, a known pathogenic factor in AD, may contribute to AD progression by increasing inflammatory mediators and disrupting the blood-brain barrier.
• Findings suggest HMGB1 signaling is a potential causal factor linking METH use to Alzheimer's disease development.